Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Funding (NCI)
Grant Awarded for Program in Cancer-Related Angiogenesis
November 24th, 1997
ImClone Systems Inc., New York, New York, announced that the company has received from the U.S. National Cancer Institute (NCI) a Phase I Small Business Innovation Research (SBIR) grant of $100,000 to support pre-clinical research on the validation of vascular-specific cadherin (VE-cadherin) as a novel potential drug target to inhibit cancer-associated angiogenesis. VE-cadherin is believed to play an important role in angiogenesis by enabling the assembly of endothelial cells into vascular tubes. Cancer growth is dependent on the formation of a capillary blood vessel network in the tumor, and VE-cadherin antagonists may thus have utility as anti-cancer agents. ImClone...
Source: Cancer Weekly (1997-11-24)
|
